绿脓菌素治疗感染的体内和体外评估

The In Vivo and In Vitro Assessment of Pyocins in Treating Infections.

作者信息

Alqahtani Abdulaziz, Kopel Jonathan, Hamood Abdul

机构信息

Clinical Laboratory Sciences, College of Applied Medical Sciences, King Khalid University, Abha 61321, Saudi Arabia.

Department of Immunology and Microbiology, Texas Tech University Health Sciences Center, Lubbock, TX 79763, USA.

出版信息

Antibiotics (Basel). 2022 Oct 7;11(10):1366. doi: 10.3390/antibiotics11101366.

DOI:10.3390/antibiotics11101366

PMID:36290026

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9598984/

Abstract

can cause several life-threatening infections among immunocompromised patients (e.g., cystic fibrosis) due to its ability to adapt and develop resistance to several antibiotics. In recent years, infections has become difficult to treat using conventional antibiotics due to the increase multidrug-resistant strains. Therefore, there is a growing interest to develop novel treatments against antibiotic-resistance strains. One novel method includes the application of antimicrobial peptides secreted by strains, known as pyocins. In this review, we will discuss the structure, function, and use of pyocins in the pathogenesis and treatment of infection.

摘要

由于其具有适应能力并能对多种抗生素产生耐药性，可在免疫功能低下的患者（如囊性纤维化患者）中引发多种危及生命的感染。近年来，由于多重耐药菌株的增加，使用传统抗生素治疗感染变得困难。因此，开发针对耐药菌株的新型治疗方法的兴趣日益浓厚。一种新方法包括应用由菌株分泌的抗菌肽，即绿脓菌素。在本综述中，我们将讨论绿脓菌素在感染的发病机制和治疗中的结构、功能及应用。